IMPORTANCE Physicians need information on how to use the first available high-sensitivity troponin (hsTnT) assay in the United States to identify patients at very low risk for 30-day adverse cardiac events (ACE).
M ore than 7 million patients annually present to US emergency departments (EDs) with symptoms suggestive of acute coronary syndrome (ACS).
1 Many of these individuals (approximately 90%) will not have an acute myocardial infarction (AMI) and will have no major adverse cardiac events (ACEs), defined as MI, urgent revascularization, or cardiac death, within the next 30 days. However, these patients are commonly hospitalized or kept under observation for an evaluation that is often negative. 2 In fact, rule-in rates in some studies approach zero. [3] [4] [5] [6] This high rate of negative evaluation occurs because of the nonspecific presentation of ACS and the potential for ACE with inappropriate discharge. There is general consensus that an acceptable ACS riskstratification strategy for discharge from the ED should identify a cohort with 30-day ACE rates less than 1%. [7] [8] [9] This 1% rate represents the breakpoint between the risk of unnecessary hospitalization resulting in morbidity from a hospital-acquired condition and the potential harm from an inappropriate ED discharge. Cardiac troponin T and I are well-established biomarkers for AMI diagnosis and outcome prediction. [10] [11] [12] However, conventional troponin assays lack the necessary sensitivity and/or precision to be used reliably for the early identification of patients at risk for 30-day ACE. 13, 14 Compared with conventional assays, high-sensitivity troponin (hsTnT) assays have significantly greater analytical sensitivity and clinical negative predictive value (NPV) for the diagnosis of AMI. 15, 16 Furthermore, they may allow the identification of a cohort of ED patients with very low 30-day ACE. 15, 16 The ability to identify patients at low risk of 30-day ACE could have a significant effect on ACS risk stratification. It could allow for more efficient inpatient resource use as well as improved patient satisfaction and reduced operational costs. Safe and rapid ED discharge could contribute to reducing pressure on EDs and decreasing wait times, thus allowing greater attention to other ED patients. The first hsTnT assay in the United States became available in January 2017 (the fifth-generation Elecsys assay). Our purpose was to evaluate the ability of this assay to identify ED patients with suspected ACS who are at very low risk for 30-day ACE.
Methods
This was a prospective, observational study of patients with suspected ACS enrolled at 15 US EDs from 2011 to 2015 (Charleston Area Medical Center, Charleston, West Virginia; Cleveland Clinic Foundation, Cleveland, Ohio; Cooper University Hospital, Camden, New Jersey; Duke University, Durham, North Carolina; Health Science Center of Houston Medical School, Houston, Texas; Henry Ford Health System, Detroit, Michigan; Indianapolis University, Indianapolis, Indiana; Mayo Clinic, Rochester, Minnesota; Minneapolis Heart Institute Foundation, Minneapolis, Minnesota; Newton Wellesley Hospital, Newton, Massachusetts; Prince George's Hospital, Cheverly, Maryland; San Francisco General Hospital, San Francisco, California; South Shore Hospital, Weymouth, Massachusetts; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; University of North Carolina, Chapel Hill; eFigure 1 in the Supplement). Roche Diagnostics, in collaboration with the clinical investigators, collected data as part of a US Food and Drug Administration (FDA) submission to evaluate the hsTnT Fifth Generation Elecsys TnT Short Turn Around Time (hsTnT Gen 5 STAT) assay (Roche Inc). All authors could request any analysis from the database and assumed responsibility for the complete manuscript and data integrity. Prior to study start, ethics approval was obtained from all relevant institutional review boards. The studies were conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization guidelines for Good Clinical Practice, and the Code of Federal Regulations 21, Part 50.
After written informed consent, patients 21 years and older presenting to the ED with symptoms of ACS were prospectively enrolled. Inclusion criteria were symptoms suggestive of ACS and ability to provide a baseline blood sample within 24 hours of symptom onset. Exclusion criteria were AMI within the last 3 months, transfer from another medical facility, surgery (including percutaneous coronary intervention) or hospitalization within the last 3 months, recent cardioversion or defibrillation, acute noncardiac primary illness prior to enrollment (eg, severe sepsis), cardiogenic shock, and pregnancy.
Serial blood samples from each patient were collected after ED presentation (once identified as a potential patient with ACS) and 3 hours, 6 to 9 hours, and 12 to 24 hours later. Clinical care was otherwise dictated by local care standards.
An independent clinical events committee (CEC), made up of 2 cardiologists and 1 emergency physician, adjudicated the rule-in AMI diagnosis for each patient per the Third Universal Definition of AMI criteria. 13 The CEC had access to all clinical data (including the local troponin assay results), but was blinded to hsTnT Gen 5 STAT results and the local diagnosis. Any discrepancies between the assigned cardiologist and emergency physician (15% of cases) were resolved by discussion or case review by the full committee. The performance of the hsTnT Gen 5 STAT assay was determined by comparison of the hsTnT assay results with the CEC-adjudicated diagnosis. Patients were followed up for 30 days to determine ACE, defined as all postdischarge death, AMI, or urgent myocardial revascularization. Follow-up was conducted via medical record review and telephone contact.
Samples were collected in lithium heparin tubes, centrifuged for 15 minutes, and stored at -70°C. Troponin T concentrations were measured by laboratory personnel blinded to sample origin identity, using the hsTnT Gen 5 STAT assay on the cobas e 601 analyzer at 1 of 4 sites. The assay is an electrochemiluminescence sandwich immunoassay, which uses both ruthenium-labeled and biotin-labeled antibodies to form a sandwich complex with troponin T. It has a specified range of 6 ng/L to 10 ng/L (all platforms) and a limit of quantification (LoQ) of 6 ng/L. Although the limit of detection for the hsTnT used in this analysis has been reported to be 3 ng/L, results less than the LoQ are not reported, per FDA regulations. Finally, no changes have occurred in the manufacture of this assay since the start of this investigation.
Reference Range Evaluation
Prior to this study, we performed a prospective, 4-center evaluation to identify the reference range for the hsTnT assay. After written informed consent was obtained, healthy individuals 21 years and older were enrolled, and blood samples were obtained to determine the 99th percentile upper reference level (URL). Inclusion criteria were no current diagnosis of cancer and no history of chronic disease (heart, cancer, renal, thyroid, respiratory [excluding asthma], autoimmune, or diabetes). Exclusion criteria included a history of ACS, pregnancy or birth within 6 weeks, currently taking prescription drugs for chronic disease, hospitalization within the previous 3 months, or blood pressure greater than 140/90 mm Hg. The 99th percentile hsTnT concentration from this cohort was subsequently used as the URL for the evaluation of diagnostic performance.
Data Analyses
Statistical analyses were performed using R, version 3.2.2 (R Foundation) 17 and SAS, version 9.4 (SAS Institute) software.
The CEC adjudication diagnosis was entered into a Code of Federal Regulations Part 11-compliant database. Clinical sensitivity, specificity, NPV, and positive predictive value (PPV) are expressed as point estimates and 95% Clopper-Pearson confidence intervals for each sample time. We also evaluated diagnostic test characteristics for the 99th percentile URL cutoff overall and for sex-specific cutoffs.
18 Cutoff-independent receiver operator characteristic curves were plotted, and the C statistic was calculated.
A post hoc analysis of serial hsTnT concentrations was performed and the NPV for 30-day ACE determined. We secondarily evaluated the effect of different 99th percentile URL cutoffs (19 ng/L vs 14 ng/L).
Because the FDA restricts results less than the LoQ from being reported, an analysis of the following hsTnT results at time 0 hours and 3 hours, respectively, was performed in patients with hsTnT results of 19 ng/L or less: less than 6 ng/L and less than 6 ng/L, less than 6 ng/L and between 6 and 19 ng/L inclusive, between 6 and 19 ng/L inclusive and less than 6 ng/L, and between 6 and 19 ng/L inclusive and between 6 and 19 ng/L inclusive. 
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Results

Reference Range Evaluation
A total of 1312 healthy individuals were enrolled in the reference range analyses, of whom 11 were excluded (blood not obtainable in 7 and inadequate sample in 4), leaving 1301 for analysis. Of these, 656 were women (50.4%); 891 were white (68.5%), 242 were African American (18.6%), 86 were Asian (6.6%), and 77 were classed as "other" race/ethnicity (6.3%). The median age was 48 years (interquartile range [IQR] , 33-55 years) and did not differ between women and men (48 years; IQR, 33-55 years and 47 years; IQR, 32-54 years, respectively). The overall 99th percentile URL hsTnT concentration was 19 ng/L. Sex-specific values were 22 ng/L and 14 ng/L in men and women, respectively. The coefficient of variation for imprecision at the URL was less than 10%.
Diagnostic Performance in Patients With Suspected ACS
A total of 1690 eligible patients with ACS symptoms were enrolled ( Figure 1 ). Of these, 1679 had hsTnT measured at 1 or more points. Follow-up information (30-day) was available for 1678 patients: 1564 were followed up by telephone (n = 1054) and/or medical records review (n = 1618), 113 were lost to follow-up, and for 1 patient, follow-up was not applicable. Patient characteristics are summarized in Table 1 . Median time from symptom onset to presentation and presentation to baseline blood draw was 2.9 hours (IQR, 1.4-6.6 hours) and 2.9 hours (IQR, 0.8-3.4 hours), respectively. Overall, 173 patients (10.3%) had an adjudicated AMI diagnosis. The sensitivities, specificities, PPVs, and NPVs for the diagnosis of AMI, using the overall and sex-specific URL, are presented in Table 2 . Diagnostic performance of the assay using 99th percentile sex-specific cutoffs (14 ng/L in women and 22 ng/L in men) was comparable with that based on the overall cutoff, with an NPV of 99.3% at 3 hours for both sexes. Because we used contemporary troponin gold standard, further research will be necessary to determine the need for sex-specific cutpoints. Overall, the C statistic for AMI at 3 hours was 0.958, with little difference between men and women (0.952 and 0.962, respectively). The sensitivity and NPV peaked/plateaued at the 3-hour sampling time. A single hsTnT measurement using the URL at baseline had inadequate performance for clinical decision making. Based on a single 3-hour sample, the sensitivity, NPV, specificity, and PPV measurements for AMI were 94.3% (95% CI, 89.1%-97.5%), 99.3% (95% CI, 98.6%-99.7%), 86.6% (95% CI, 84.6%-88.4%), and 43.6% (95% CI, 37.9%-49.4%), respectively. Unfortunately, based on hsTnT alone, there were 8 falsenegative results at 3 hours (Table 2) ; none of these patients experienced an additional ACE during the 30-day follow-up. Overall, of 1355 patients with serial hsTnT results at 0 hours and 3 hours (Figure 2A ), 1052 had a non-AMI CEC diagnosis. There were 1264 patients with hsTnT results at 0 hours and 3 hours and who had 30-day follow-up information ( Figure 2B ), of whom 290 (22.9%) had a hsTnT level exceeding the URL (>19 ng/L) at either point. This non-rule-out cohort had a 30-day ACE rate of 2.8% (n = 8) vs 0.7% (n = 7) in the 974 patients (77.1%) with both serial hsTnT measurements that were less than the URL. Serial hsTnT levels less than the URL resulted in a 99.3% NPV for 30-day ACE ( Figure 2B ). None of the 7 patients with serial 3-hour time false-negative results experienced AMI or death within the subsequent 30 days.
Troponin trajectory was evaluated in greater detail in 974 patients with an hsTnT level of 19 ng/L or less at 0 and 3 hours. For most of these patients, the hsTnT result did not cross the LoQ margin during the 3 hours but had either both measures less than (n = 559; 57.4%) or both greater than (n = 345; 35.4%) the LoQ (6 ng/L). Their NPV for 30-day ACE was 99.3 and 99.1%, respectively. Only 70 patients had their hsTnT result rise (n = 35) or fall (n = 35) across the LoQ during the 0-hour and 3-hour sampling. Both of these cohorts had a 100% NPV for 30-day ACE ( Figure 2B) . Figure 3 presents the assay's diagnostic performance based on various cutoffs. Using a cutoff of less than 6 ng/L for baseline hsTnT concentrations (n = 1600) provided an AMI NPV of 99.4% (95% CI 98.6-99.8) and ruled out AMI in 50.3%. At 3 hours, the less than 6 ng/L cutoff (n = 1415) gave an NPV of 99.7% (95% CI, 99.0-100.0) for AMI rule-out in 48.7%.
Because clinicians were blinded to hsTnT, we evaluated index visit hospitalization (defined as length of stay greater than 24 hours) and coronary revascularization rates in patients with a 0-hour and 3-hour hsTnT levels of 19 ng/L or less (57.5% and 3.6%, respectively) vs the cohort with hsTnT levels greater than 19 ng/L (89.2% and 21.8%, respectively). Because of the time difference between presentation and hsTnT measurement, a sensitivity analysis was performed at the single baseline hsTnT before and after 6 hours following symptom onset. While there were no statistical differences in performance, improvements in sensitivity (82%-90.7%) and NPV (97.6%-98.9%) occurred at the cost of specificity (88.8%-86.9%) and PPV (47.4%-42.8%), with longer times.
Because the rest of the world uses a lower URL (14 ng/L) than the United States, an analysis of the diagnostic reclassification occurring between URLs was performed. This analysis found only 2 of 140 CEC-confirmed AMIs having hsTnT values between the 2 URLs at the 3-hour sampling point (eFigure 2intheSupplement). 
Discussion
We report that, in patients presenting to US EDs with suspected ACS, hsTnT levels identified a large proportion at very low 30-day ACE risk. Identifying a low-risk cohort may permit early ED discharge and avoid unnecessary hospitalization. Rapid turnaround of low-risk patients could translate into a reduction in ED volumes, which would benefit patients (shorter waiting times, increased satisfaction, improved outcomes, and saved costs), clinicians (decreased diagnostic ambiguity and medicolegal burden), and hospitals (by providing cost-saving benefits).
19-21
In this analysis, we used a hsTnT URL cutoff level of 19 ng/L. Derived from a healthy cohort, it represents the 99th percentile in the United States, consistent with the Third Universal Definition of AMI.
13 This cutpoint exceeds the 14 ng/L used globally and may be explained by geographically dependent cardiovascular risk. 22, 23 When applied in clinical practice, the clinician must consider the similarities of their population to that used for the derivation of this cutpoint because the 99th percentile is entirely dependent on the reference study population. We also evaluated sex-specific URLs (14 ng/L for women and 22 ng/L for men) and found diagnostic performance was largely unchanged, in contrast to a prior report with highsensitive troponin I reporting a doubling of the female AMI rate with sex-specific URLs.
24,25
Based on the 19 ng/L cutoff and compared with a CECadjudicated clinical diagnosis, the hsTnT assay had excellent 290 Non-rule-out 8 ACE (2.8%) sensitivity and NPV for the diagnosis of AMI and 30-day ACE.
Values for sensitivity and NPV at the 3-hour sampling point exceeded 99%, such that a 3-hour point may be adequate for the early rule out of AMI using the 99th percentile URL. We do note that the high sensitivity and NPV were achieved at the cost of a lower specificity and PPV. Importantly, we demonstrate a very low rate of falsenegative results, associated with only limited clinical consequences. None of the seven 3-hour time false-negative results were associated with AMI or death in the subsequent 30 days. We also evaluated the false-negative results between 0 and 3 hours to determine whether the magnitude of a serial hsTnT change (ie, the Δ) could be predictive. Of the 8 falsenegative results, 6 did not have a hsTnT change greater than 22 ng/L, thus limiting the clinically utility of applying a serial change (Δ).
An ACS diagnostic strategy with NPV of 99.3% for 30-day ACE is clinically useful and acceptable. In this cohort, the NPV for 30-day ACE exceeded 99% in all subgroups with hsTnT levels of 19 ng/L or less at 0 and 3 hours. A rule-out strategy based on a single hsTnT at presentation and using lower cutoffs has been proposed by others. 26, 27 However, in our study, a single hsTnT level of 19 ng/L or less is probably inadequate because it provided an AMI NPV of only 98.2% at baseline presentation. Conversely, use of the LoQ cutoff (6 ng/L) may represent a potential option because it demonstrated an AMI NPV of 99.4%. The median time from symptom onset to ED presentation was 2.9 hours, while time from symptom onset to baseline hsTnT was 5.8 hours. Clinicians should consider that the performance characteristics of hsTnT may not be duplicated at earlier times.
Limitations
This study has several limitations in the clinical application of its results. First, as an observational analysis with the results blinded to the clinician, no clinical decision making occurred as a result of the hsTnT results, although fewer patients were hospitalized in the rule-out cohort (57.5%) vs the rule-in cohort (89.2%). Some patients with a negative hsTnT were hospitalized and may have derived clinical benefit. Ergo, we cannot comment on how knowledge of the hsTnT results may have affected clinical outcomes. Second, patients likely to have non-ACS elevations of hsTnT (eg, recent prior AMI or renal insufficiency) were excluded from enrollment in this trial; thus, the patients enrolled in this study should be considered when making clinical decisions. Third, these data are not applicable to environments that do not use the identical assay because hsTnT and hsTnI testing results are not interchangeable. Fourth, our event rate was low, as is consistent with contemporary ED practice. Fifth, by the constraints of a study, median time to the baseline hsTnT draw was 5.8 hours. While this did not statistically change the performance of the assay, physicians should consider that shorter times between symptoms and hsTnT measurement result are likely to result in a deterioration of NPV. Additionally, we did not use a clinical risk-stratification tool (eg, Emergency Department Assessment of Chest Pain Score [EDACS]; History, ECG, Age, Risk Factors, and Troponin [HEART] Score; or Thrombolysis In Myocardial Infarction [TIMI] Score). This has the advantage of avoiding reliance on subjectively gathered information; however, the potential for risk stratification tools to affect a "one-and-done" single troponin strategy requires additional investigation. Finally, because of the blinded nature of the hsTnT, we cannot present the additional diagnostic effect of hsTnT against standard clinical criteria.
Strengths of the study include that the reference range population was representative of the US population (with the caveat that most of participating hospitals were larger academic centers) and generally in line with National Hospital Ambulatory Medical Care Survey data for patients receiving cardiac biomarker testing in the ED, more than double the size of the International Federation of Clinical Chemistry criteria, 28, 29 and is relevant to the region where the test is used most. Furthermore, the precision criteria of the assay at the cutoff met the criteria defined in the third universal definition of AMI. 13 Finally, we focused on a clinically relevant outcome (NPV) to identify patients potentially safe for early ED discharge.
Conclusions
In this multicenter evaluation, we demonstrated that a 0-hour and 3-hour hsTnT assay using less than 6 ng/L provides a safe and early rule-out for AMI and identified a large cohort of patients with suspected ACS at very low risk of 30-day ACE.
Peacock reports grants from Roche Inc during the conduct of the study; grants and personal fees from Roche Inc and Alere Inc; and personal fees from Abbott Inc, Beckman Inc, and Prevencio Inc outside the submitted work. Dr Baumann reports grants from Roche during the conduct of the study (payment for enrollment of patients in this investigation to cover salary support of research coordinator). Ms Bruton reports previous employment with Roche Diagnostics. Dr Handy reports funding from Roche Diagnostics to support laboratory personnel and supplies for the study (study design and statistical analysis), during the conduct of the study and has participated in other studies with Roche Diagnostics in which funding to support laboratory personnel and supplies (study design and statistical analysis) was provided for the study outside the submitted work. Dr Jones reports grants from Roche Diagnostics Inc during the conduct of the study and grants from Janssen and AstraZeneca outside the submitted work. Dr Hollander reports grants from Roche during the conduct of the study and grants from Alere, Siemens, Roche, and Trinity outside the submitted work. Dr Limkakeng reports grants from Roche Diagnostics International Ltd during the conduct of the study; consultancy from ZS Pharma and Biomerieux; and grants/grants pending from Roche Diagnostics, Abbott Laboratories, Bristol Meyers Squibb, Siemens Healthcare, Department of Defense/Henry Jackson Foundation, and Janssen Pharmaceuticals outside the submitted work. Dr Mehrotra reports sponsored research from Roche during the conduct of the study. Dr Than reports grants and personal fees from Abbott and Roche (funding for clinical trials, payment for speaking, and funding for education), grants from Beckman (funding for clinical trials, funding for education), and personal fees from Alere (payment for speaking and funding for education) outside the submitted work. Dr Ziegler reports employment with Roche Diagnostics during the conduct of the study. Ms Dinkel reports employment by Roche Diagnostics. No other disclosures were reported.
Funding/Support: This study was sponsored and funded by Roche Diagnostics, Penzberg, Germany.
Role of the Funder/Sponsor: The funding source had a role in the design and conduct of the study and collection, management, initial analysis of the data. It did not have a role in the interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. • Page 28, 7.5.2 the following was added: o Clarification of chronic diseases and prescription medications that will determine exclusion.
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Study abstract
The concentration of troponin in prospectively collected specimens from apparently healthy subjects for a reference range study will be measured using the Roche Elecsys Troponin T Gen 5 assay at three (3) external US sites on both the cobas e411 and e601 immunoassay analyzers. This Multicenter sample collection study will be designed to obtain samples from a minimum of four (4) collection sites within the U.S. for testing. A minimum of 1200 evaluable subjects who meet the inclusion criteria will be required for this Reference Range enrollment. Template: GuiDoc_StudyProt_PerfEval_v7.doc
Overview study design
The experimental part is subdivided into the following main sections:
Clinical Program (see 7)
A clinical study can be performed if relevant background information of patient samples is required and available.
PICO criteria have to be applied P = Patient population definition Healthy subjects I = Index/product/marker to be studied Elecsys Troponin T Gen 5, cardiac marker
O = Outcome
To validate the 99 th percentile of the Troponin T Gen 5 assay
List of experiments and acceptance criteria
All volunteer subjects will have to meet the inclusion criteria (see detailed Inclusion / Exclusion criteria in Section 7.0 of this protocol). Sample testing by the Troponin T Gen 5 assay by both the STAT and 18 minute assays on the cobas e411 and e601 immunoassay analyzers will occur under a separate testing protocol. INTRODUCTION
General note
The Elecsys Troponin T Gen 5 product will not be provided to the Principal Investigators or to the subjects of the sample collection aspect of the study. Sample testing will be conducted at 3 external testing laboratories under a separate testing protocol. Sample collection is required for further technical and clinical validation through comparative, parallel measurement with established methods. Documents and data of this study will be handled confidentially.
The Principal Investigator must ensure that the clinical study will be conducted in accordance with the following:
• Signed service or clinical study agreement with Roche Diagnostics Operations, Inc.
(Roche Diagnostics) • Signed study protocol provided by the Roche Study Manager • All general Good Clinical Practice (GCP) and country-specific or state regulations applicable to the clinical study • Signed Investigator's Agreement with Roche Diagnostics
Product/method description
The new Elecsys TnT Gen 5 assay has an improved analytical sensitivity compared to earlier test generations which was achieved by a formulation change while still using the same epitope-directed monoclonal antibodies as in the earlier test versions.
The improved signal/noise ratio was mainly achieved by increasing the sample volume from 15 to 50 μL. The test uses both ruthenium-labeled and biotin-labeled antibodies to form a sandwich complex with troponin T. The formed immune complexes are immobilized onto the surface of magnetic microparticles via biotin-streptavidin binding. The measured electrochemiluminescence (ECLIA technology) signal is proportional to the amount of troponin T in the sample. The test has a turnaround time of either 9 minutes (STAT assay) or 18 minutes and is dedicated to run on all Elecsys and cobas e analyzers. Template: GuiDoc_StudyProt_PerfEval_v7.doc
2.3
Objective of the study
The purpose of this study for the performance and labeling claims for the Elecsys Troponin T Gen 5 assay on the Elecsys and cobas e analyzers using specimens which represent the clinical population defined in the intended use. The medical decision value for the aid in AMI diagnosis is derived from troponin measurements in a healthy subject cohort (99th percentile) which is the major purpose of present study.
Intended use
Immunoassay for the in vitro quantitative determination of cTnT in human serum and plasma. The assay is intended as an aid in the diagnosis of myocardial infarction. The electrochemiluminescence immunoassay "ECLIA" is intended for use on the indicated Elecsys and cobas e immunoassay analyzers.
Ethical Considerations
Each investigator will ensure that this study is conducted in full conformance with the principles of the "Declaration of Helsinki" (as amended in Tokyo, Venice and Hong Kong), or the country specific regulations that will apply in accordance with the principles laid down in the Convention of the Council of Europe for the protection of human rights and dignity of the human being with regard to the application of biology and medicine and by any national regulations on this matter or with the laws and regulations of the country in which the determination is conducted, whichever affords the greater protection to the individual. The results obtained from a specimen by means of the Investigational Use Only (IUO) device under evaluation shall not be used for other purposes than for performance evaluation. To adequately protect the subjects involved in medical research, the investigator must obtain approval or waiver from an Institutional Review Board (IRB) or the Independent Ethics Committee (IEC), observe Subject confidentiality, and must not use data in Subject management. Non-Disclosure Agreement Must be signed and dated by the Principal Investigator prior to protocol review.
Evaluation contract or agreement
The contract must be signed by the Sponsor and the party of the Principal Investigator prior to the start of the study.
Study protocol Last (signature) page must be signed as accepted by the Investigator and returned to RD before study start.
Site specific protocol Overview of agreed upon experiments -must be completed and signed by the evaluator prior to study start, if applicable.
Financial disclosure Confirms that the Principal Investigator has no financial interest in the sponsor.
Financial Disclosure forms must be signed by the Principal Investigator and any Sub-Investigator(s) prior to study start. Updates will be required, if personnel change during the study, or if financial disclosure information changes during and up to one year after the study is closed.
Delegation of responsibilities by the Principal Investigator 2 Alignment of roles & responsibilities within the site evaluation team.
If documents or forms will be signed by others (sub-investigators or study staff), a Delegation of Responsibilities form must be completed and signed and dated by the PI at Study Initiation, during the study if there are any changes, and at study closure.
EC/IRB approval incl. informed consent (if needed) or waiver
Approval letter (signed and dated) from Institutional Review Board (IRB)/EC, including name and study number on the cover of this protocol. The IRB/EC approval or a statement ("waiver") that IRB/EC approval is not necessary must be provided prior to initiation of the study. A list of IRB/EC members or a statement verifying that the IRB/EC is an appropriately constituted body should also be provided. Relevant correspondence and documentation supporting subsequent reviews and approvals must also be maintained (protocol amendments, periodic reviews, etc.). 
Document Comments
QC documents Laboratory certifications, accreditation certificates, participation in external quality assessment schemes.
Curriculum vitae
Copies of signed and dated Curriculum Vitae (CV) of Principal Investigator must be provided prior to study start. Study team members must provide a CV and/or objective evidence of their qualifications prior to their participation in the study. Updates will be required if personnel change during the study.
Training record Signed and dated documentation for all study team members what has been trained and discussed before/upon initiation of the study.
Documents required during study and at study completion (where appropriate, forms & documents will be supplied by RD for completion and signature)
Material receipt Signed and dated Material Receipt forms (fax back to Roche Diagnostics as directed on the form) throughout the conduct of the study should be provided.
Material balance Not applicable. No investigational use materials will be sent to any site as part of this collection protocol.
Site specific protocol Overview of agreed upon experiments -must be cross-checked and signed after close-out. Optional for collection studies.
Package insert from comparison system(s)
Copy (signed and dated if appropriate).
Signed and dated Case Report Forms (for clinical studies)
To be provided at latest by end of the study or agreed-upon time intervals.
Signed and dated instrument print-outs including competitor systems or results captured via WinCAEV (e-signed and dated) This is not applicable to this collection protocol.
Daily log This is not applicable to this collection protocol.
Correspondence (e.g. Telephone log and emails) Documentation of verbal and written communication between including email, fax and telephone communications between RD, the Investigator(s)and all study site personnel throughout the study. 
Summary letter of the Principal Investigator
MATERIALS
Please note:
With each shipment of material you will receive a copy of the delivery note (' Material Receipt') listing the exact amount and lot number of the material. Please check if the material was delivered completely, confirm the delivery by your signature and send back the delivery note to your contact person at Roche Diagnostics as soon as possible.
Materials provided by Roche Diagnostics
Materials
Sample collection kits*
Site Binder
Remote Data Entry (EDC, electronic data capture) *Sample Collection Kits will include the following:
Two 8 mL Li Heparin with polymer separator gel (PST) light green top tube labeled with a unique identifier barcodes. Three 8.5 mL Serum red top tube labeled with a unique identifier barcodes.
• Sixteen aliquot (cryovials) vials labeled with a unique barcode will be provided for each matrix.
• Paper Case report forms (data is entered remotely via EDC)
• Freezer boxes and supplies for the shipping of aliquots to Roche Diagnostics
• Federal Express or equivalent pick-up and drop-off services Collection kits for specimen collection will be provided by Roche Diagnostics after the service or clinical study agreement has been signed and dated by the clinical study site and Roche Diagnostics prior to study initiation. 250 -500* (~1600 total from all sites) prospectively collected healthy subjects per site using Informed Consent. *For Version 3 of this protocol an additional 100-150 subjects will be requested from each collection site.
• Appropriate number of skilled medical personnel 
EVALUATION REQUIREMENTS
Personnel required for the study
At least one to two clinical coordinators familiar with Informed Consent and ICH Guidance on Good Clinical Practice is necessary for up to 30 weeks to enroll the Reference Range Cohort of subjects.
Roche Diagnostics Monitoring/Auditing Responsibilities
Roche Diagnostics is responsible for qualifying, initiating, monitoring and closing out all studies with full documentation. Roche Diagnostics requires demonstration of the quality system in use in the laboratory for ensuring that the results recorded on the case report forms, data sheets and in study log are accurate. Responsibility for the quality system lies with the laboratory; however, in case of questions about recorded information, Roche may request access to original source documents. Roche may also request to review recent CLIA (Clinical Laboratory Improvement Act 1988), CAP (College of American Pathologists) and other appropriate inspection agency reports as part of the on-going quality system validation in the site.
As part of the monitoring process, an audit of subject records and original (source) data will occur; the Principal Investigator must agree to facilitate the review of original source data as requested by the Roche Diagnostics study monitor or another designated representative from Roche.
All records, copies of correspondence with Roche and with the EC/IRB (Ethics Committee /Institutional Review Board) and all subject files will be maintained at the evaluation site for the period of time agreed upon in the clinical study agreement following completion of the study if not specified otherwise. All original source data (data printouts) will be sent to RD; if no online data transfer (e.g. MACRO) is performed. The Principal Investigator will be responsible for insuring that the full records are maintained.
The Roche Diagnostics Site Monitor will provide assistance in arranging the documentation of files, which may be audited by regulatory authorities at the site. Subject confidentiality will be strictly maintained. 
Documentation
Protocol activities must be documented via the appropriate Informed Consent and electronic Case Report Form (eCRF). The collection site recruits subjects, completes informed consent documents, completes CRF pages (EDC), collects and processes the samples and then transfers the samples to Roche Diagnostics.
5.4
Sample/ patient recruitment
Collection of samples
The collection should be done in compliance to common/local ethical principles and under consideration of subject's rights and subject's safety.
Subject specimens
The recruitment of suitable study subjects is dependent on the inclusion and exclusion criteria. See detailed Inclusion/Exclusion criteria in Section 7 of this protocol.
Aliquots for each clinical specimen have to be labeled with a unique barcode specific for the subject and the time point of blood draw.
To enable proper testing, experiments have to be accomplished with equally treated specimen. Therefore aliquots have to be prepared within 8 hours of the blood draw. See detailed instructions for sample collection and preparation in Section 7.6.4 of this protocol.
CRFs have to be entered into the EDC (validated, internet-accessible, server based database).
Data Management Plan
A database will be prepared for capturing the eCRF information in electronic database (EDC). The Reference Range cohort will require input into a specific CRF database, EDC. Each collection site will be trained and responsible for remote data entry. The EDC database will be monitored against source data according to an established Monitoring Plan. It is understood that subject recruitment rates are based on reasonable planning expectations. The Principal Investigator shall continuously compare the actual and expected recruitment rates and make every effort to ensure that they are as closely matched as possible. If the Principal Investigator anticipates major problems with recruitment or a delay in expected completion date, the Principal Investigator shall discuss this with the Study Monitor as early as possible. In clinical studies special emphasis has to be on the real time review of incoming clinical information linked to the subjects' medical history.
EDC information and data from the testing sites will be combined into a SAS-based Once the testing and review including Source Data Verification (SDV) is completed, a final data extraction will be conducted according to the statistical analysis plan. This collection of data output tables will be representative of the official locked SAS database and will become the source of data for the Study Report. A final Excel export of the database will also serve as the data line listing that will be submitted to the FDA. The data extraction outputs (SAS database) and the line listing (Excel) will be completely consistent.
Environmental Instructions
Biohazardous material should be disposed of in alignment with the national and local environmental regulations as well as the policies of the facility.
Safety
All human material should be considered potentially infectious. It is recommended that all human-sourced samples be handled in accordance with the US Department of Labor Occupational Safety and Health Administration's standard on blood-borne pathogens (29 CFR 1910 (29 CFR .1030 ).
Dispose of hazardous or biologically contaminated materials according to the practices of your institution. Discard all materials in a safe and acceptable manner, and in compliance with your local requirements.
5.8
Sample size / statistical methods
Rationale for the Sample Size
There are three factors to consider when composing the reference study population:
• Gender should be balanced to be representative for the real population. This ensures equal numbers for both gender groups.
• Race distribution of the reference study should be representative for the US population. Appropriate recruitment rates are to be regarded.
• Age is normally quite high in the intended use population (subjects presenting to the emergency department with symptoms suggestive of acute coronary syndrome), especially in comparison to the age levels commonly appearing in reference studies. Recruitment rates for the reference study shall ensure a roughly similar age distribution as it is expected in the intended use population. 
Statistical methods
Method for calculating percentiles for the reference ranges is using inverse cumulative distribution function with averaging at discontinuities as also implemented in commonly used statistical software (e.g. R: version 3.0.1, package stats, function quantile: type=2 or SAS: version 9.3, univariate procedure, pctldef= 5). Method for calculating nonparametric confidence intervals for percentiles is the approach by Hahn and Meeker. Analyses are described in more detail by the Statistical Analysis Plan (SAP).
Study Documentation, Record Keeping and Data Transfer
The Principal Investigator, or authorized designee, must complete all study documentation provided by the Sponsor using non-erasable pens. The Principal Investigator shall supply Roche Diagnostics on request with any required background data of these records. In case of special problems and/or governmental queries, it is also necessary to have access to the complete study records. In cases where de-identified samples are used the Study Protocol will be assessed by ethic committees/IRBs of the respective countries.
Copies of records must be stored at the Site after the product has been approved as agreed upon in the clinical study agreement. In the event that these storage conditions cannot be met, the investigator must contact Roche and make arrangements for the transfer of the records.
Study Documentation Practices
The investigator must maintain adequate records to enable the conduct of the study to be fully documented.
a) All records, including electronic forms, must be filled out completely. Complete each space or blank. If there is no information to go into a space or blank, then use the symbol "N/A". If an entire section or page of a record is "N/A", it is acceptable to indicate this by drawing one line through the entire section/page and use "N/A" near that line. It is acceptable to check a box marked "N/A" to indicate that a section or an entire page is not applicable. b) The use of 'Wite-Out' or similar correction fluid is forbidden. c) Handwritten dates are always to be recorded in the sequence of the month, day and year (mm/dd/yy or yyyy) unless otherwise specified. d) Erasable pens and pencils are not permitted. e) Use of highlighters on records is acceptable so long as the highlighter color does not obscure the underlying text if the record is copied. Template: GuiDoc_StudyProt_PerfEval_v7.doc f) Accuracy is required. Always verify entries are correct and consistent with other information. g) Signatures are to be authentic. h) Recorded dates are to be the actual dates in which the activities were recorded. Backdating is forbidden. i) If drinks or chemicals are spilled on original records, dry them off to the best of your ability, make an immediate photocopy and make a notation of the event on the copy. Retain the original record except in the event of contamination with a hazardous material. j) All forms must be filled out using non-erasable pen and must be legible. The use of blue or black ink is preferred. k) Errors must be crossed out with a single line, the correction inserted, and the change initialed and dated by the approved person making the correction. The reason for the correction must be stated.
Protocol Modifications
Protocol modifications to ongoing studies which alter the scope of the investigation, the scientific quality of the study, the experimental design, assessment variables, or the number of patients / subjects must be made only after appropriate consultations between the Study Manager and the Principal Investigator(s). Such fundamental changes to the design or conduct of the study must be documented as a new version of the original Study Protocol.
New versions of the Study Protocol must be signed and dated by the Principal Investigator, submitted to the IRB where applicable and stored in the corresponding study binder. Approval must be obtained by the Sponsor, the IRB/IEC, Regulatory or other applicable parties prior to implementing any protocol revisions.
Protocol Deviations
Protocol Deviations to ongoing studies are any unapproved changes in the study design and/or procedures that are within the Investigator's control and not in accordance with the IRB approved protocol. The Investigator has to contact the Study Monitor for any protocol deviation. The Monitor will complete the Protocol Deviation form provided in the Study Binder. Additionally, the reviewing IRB has to be contacted by the Investigator if a Protocol Deviation might either affect the participant's right, safety or well-being, or might significantly affect the completeness, accuracy and reliability of the data. The Protocol Deviation form in use at the site or the form provided by Roche Diagnostics can be used for this purpose. Roche Diagnostics and the Principal Investigator reserve the right to terminate the study. One reason for this might be protocol violation. Shall this be necessary, the procedures for early termination will be arranged on an individual study basis after review and consultation by both parties. In case of EC/IRB involvement this institution (Roche Diagnostics) shall be informed.
Withdrawal of informed consent for the Individual Subject:
• The patient or subject is free to stop his participation of the study and withdraw his informed consent whenever he wants without mentioning any reason and without any influence on his treatment later on. In these cases all data, except for the original informed consent, will be omitted from the study files. A Patient ID with a comment "withdrawal of informed consent" will remain in the records only.
• The occurrence of adverse events or adverse device effects in a patient/subject which lead to a termination of the study due to medical reasons.
Publication of Data and Protection of Trade Secrets
The results of this study may be submitted to regulatory authorities in support of product clearance. Any results of this study may be published or presented at scientific meetings. If this is anticipated, the Principal Investigator agrees to inform Roche Diagnostics and to submit all manuscripts or abstracts prior to submission. All publications and lectures with any reference to the object of this agreement need the previous written consent of Roche Diagnostics. If the study is part of a multi-center study, the Investigator agrees that the first publication of his results will be made in conjunction with a joint multi-center publication including results of all participating investigators and institutions. There may be additional detailed agreements on publications in the contract. Any formal publication of the study in which the input of Roche Diagnostic's personnel exceeds that of conventional monitoring will be considered as a joint publication by the Investigator and the appropriate RD staff. Authorship will be determined by mutual agreement. 
Confidentially of Study Documents and Subject Records
Required by law the Principal Investigator must assure that patients/subjects confidentiality be maintained. Under no circumstances shall any records sent to Roche Diagnostics reveal subject identity by the use of subject names, social security numbers, or any other means. If your institution employs a subject identification numbering system that breaches subject confidentiality, study specific subject identification numbers must be generated. A crossreference sheet (Sample Identification Log) can be provided for your use if necessary. This data sheet shall not be copied and sent to Roche Diagnostics. It shall remain in your Site Binder only. Case Report Forms whether paper or EDC will reflect the assigned Subject ID number.
The conduct of this product evaluation should be guided by the principles of Good Clinical Practice (GCP).
• The investigator must assure that patients' (subjects') confidentiality will be maintained.
• Capture of clinical data may be facilitated using CIM software (EDC / Macro) provided by Roche Diagnostics.
The subject data required in the Case Report Forms must be complete and accurate. Information shall be entered into the EDC or on the paper CRF and shall accurately correspond to source documents. Data entry should be completed on the paper CRF or in the EDC database as soon as possible after the subject information is obtained. All subject data will be verified against the source data by Roche personnel. The CIM software / EDC are a 21 CFR Part 11 compliant database which is accessed via the internet using a Roche issued Secure ID. 
Definition of SAE
Serious adverse events (SAEs) are a subset of AEs. A SAE is defined as any untoward medical occurrence or event that:
1) Led to death 2) Is life-threatening 3) Results in a permanent or significant disability/incapacity, impairment of a body structure or a body function 4) Requires in-subject hospitalization or prolongation of existing hospitalization (usually involving at least an overnight stay) 5) Results in an important medical event or requires intervention to prevent one or other of the outcomes listed above
In this Reference Range study an SAE is defined as an AE that is related to the blood-draw and meets with one or more of the above criteria for SAEs.
Some examples, but not all inclusive, of SAEs related to the blood draw are:
-Hospitalization and prolongation of hospitalization -Emergency Room Visit
